| Year |
Citation |
Score |
| 2019 |
Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, et al. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 35: 738-751.e9. PMID 31085175 DOI: 10.1016/J.Ccell.2019.04.006 |
0.593 |
|
| 2016 |
Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, et al. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. PMID 27927766 DOI: 10.3324/Haematol.2016.152710 |
0.532 |
|
| 2015 |
Smith BD, Kaufman MD, Leary CB, Turner BA, Wise SC, Ahn YM, Booth RJ, Caldwell TM, Ensinger CL, Hood MM, Lu WP, Patt TW, Patt WC, Rutkoski TJ, Samarakoon T, et al. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Molecular Cancer Therapeutics. 14: 2023-34. PMID 26285778 DOI: 10.1158/1535-7163.Mct-14-1105 |
0.568 |
|
| 2015 |
Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. Journal of Medicinal Chemistry. 58: 4165-79. PMID 25965804 DOI: 10.1021/Acs.Jmedchem.5B00067 |
0.567 |
|
| 2015 |
Smith BD, Hood MM, Wise SC, Kaufman MD, Lu W, Rutkoski T, Flynn DL, Heinrich MC. Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models Cancer Research. 75: 2690-2690. DOI: 10.1158/1538-7445.Am2015-2690 |
0.577 |
|
| 2014 |
Moon S, Bannen RM, Rutkoski TJ, Phillips GN, Bae E. Effectiveness and limitations of local structural entropy optimization in the thermal stabilization of mesophilic and thermophilic adenylate kinases. Proteins. 82: 2631-42. PMID 24931334 DOI: 10.1002/Prot.24627 |
0.31 |
|
| 2013 |
Rutkoski TJ, Kink JA, Strong LE, Raines RT. Human ribonuclease with a pendant poly(ethylene glycol) inhibits tumor growth in mice. Translational Oncology. 6: 392-7. PMID 23908681 DOI: 10.1593/Tlo.13253 |
0.567 |
|
| 2013 |
Bianchetti CM, Brumm P, Smith RW, Dyer K, Hura GL, Rutkoski TJ, Phillips GN. Structure, dynamics, and specificity of endoglucanase D from Clostridium cellulovorans. Journal of Molecular Biology. 425: 4267-85. PMID 23751954 DOI: 10.1016/J.Jmb.2013.05.030 |
0.342 |
|
| 2011 |
Rutkoski TJ, Kink JA, Strong LE, Raines RT. Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity. Cancer Biology & Therapy. 12: 208-14. PMID 21633186 DOI: 10.4161/Cbt.12.3.15959 |
0.578 |
|
| 2011 |
Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 19: 556-68. PMID 21481795 DOI: 10.1016/J.Ccr.2011.03.003 |
0.585 |
|
| 2010 |
Rutkoski TJ, Kink JA, Strong LE, Schilling CI, Raines RT. Antitumor activity of ribonuclease multimers created by site-specific covalent tethering. Bioconjugate Chemistry. 21: 1691-702. PMID 20704261 DOI: 10.1021/Bc100292X |
0.595 |
|
| 2008 |
Rutkoski TJ, Raines RT. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Current Pharmaceutical Biotechnology. 9: 185-9. PMID 18673284 DOI: 10.2174/138920108784567344 |
0.583 |
|
| 2007 |
Fuchs SM, Rutkoski TJ, Kung VM, Groeschl RT, Raines RT. Increasing the potency of a cytotoxin with an arginine graft. Protein Engineering, Design & Selection : Peds. 20: 505-9. PMID 17954521 DOI: 10.1093/Protein/Gzm051 |
0.645 |
|
| 2007 |
Lavis LD, Rutkoski TJ, Raines RT. Tuning the pK(a) of fluorescein to optimize binding assays. Analytical Chemistry. 79: 6775-82. PMID 17672523 DOI: 10.1021/Ac070907G |
0.594 |
|
| 2005 |
Rutkoski TJ, Kurten EL, Mitchell JC, Raines RT. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A. Journal of Molecular Biology. 354: 41-54. PMID 16188273 DOI: 10.1016/J.Jmb.2005.08.007 |
0.566 |
|
| Show low-probability matches. |